kuliah alergi obat - dr mohammad eko irawanto.pptx
TRANSCRIPT
FB: Eko Kepik - HP: 08122914685 15 Nov 2015
ADVERSE CUTANEOUSDRUG REACTIONS
Muh. Eko IrawantoBag/SMF Ilmu Kesehatan Kulit dan Kelamin FK UNS/ RS dr Moewardi Surakarta
FB: Eko Kepik - HP: 08122914685 25 Nov 2015
FB: Eko Kepik - HP: 08122914685 35 Nov 2015
FB: Eko Kepik - HP: 08122914685 45 Nov 2015
FB: Eko Kepik - HP: 08122914685 55 Nov 2015
FB: Eko Kepik - HP: 08122914685 6
Urtikaria
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 7
Acute generalized exanthematous pustulosis (AGEP)
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 8
Drug Reaction with Eosinophilia and SystemicSymptoms (Drug-Induced Hypersensitivity Syndrome) / DRESS / DIHS
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 95 Nov 2015
FB: Eko Kepik - HP: 08122914685 105 Nov 2015
FB: Eko Kepik - HP: 08122914685 11
Angioedema
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 12
Vasculitis
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 13
EXANTHEMATOUS DRUG REACTIONS
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 14
EXANTHEMATOUS DRUG REACTIONS
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 15
EPIDEMIOLOGY Age of Onset
Less common in the very young. Incidence
Most common type of cutaneous drug reaction
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 16
ETIOLOGY Drugs with a high probability of reaction (3 –
5%): penicillin and related antibiotics, carbamazepine, allopurinol, gold salts (10–20%).
Medium probability : sulfonamides (bacteriostatic, antidiabetic, diuretic), nonsteroidal anti-inflammatory drugs (NSAIDs), hydantoin derivatives, isoniazid, chloramphenicol, erythromycin, streptomycin.
Low probability (<1%): barbiturates, benzodiazepines, phenothiazines, tetracyclines
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 17
PATHOGENESIS Exact mechanism unknown. Probably delayed hypersensitivity.
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 18
CLINICAL MANIFESTATIONS
Onset Early Reaction In previously sensitized
patient, eruption starts within 2 or 3 days after readministration of drug.
Late Reaction Sensitization occurs during administration or after completing course of drug; peak incidence at ninth day after administration.
However, ACDR may occur at any time between the first day and 3 weeks after the beginning of treatment.
Reaction to penicillin can begin ≥2 weeks after drug is discontinued.
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 19
Skin Symptoms Usually quite pruritic, disturbs sleep. Painful skin lesions suggest development
of a more serious ACDR, such as TEN. Systems Review
Fever, chills.
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 20
Skin Lesions Macules and/or papules, a few millimeters to
1 cm in size (Figs. 22-1 and 22-2). Bright or “drug” red. Resolving lesions have hues of tan and purple. In time, lesions become confluent forming
large macules, polycyclic/ gyrate erythema, reticular eruptions, sheetlike erythema (Fig. 22-1), erythroderma; alsoerythema multiforme–like.
Scaling and/or desquamation may occur with healing.
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 21
Distribution Symmetric (Fig. 22-1). Almost always on trunk and extremities. Confluent lesions in intertriginous areas,
i.e., axilla, groin, inframammary area. Palms and soles variably involved. In children, may be limited to face and
extremities.
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 225 Nov 2015
FB: Eko Kepik - HP: 08122914685 235 Nov 2015
FB: Eko Kepik - HP: 08122914685 24
Exanthematous drug eruptions. Numerous pink papules on the trunk due to a cephalosporin (A). Confluence of lesions on the trunk (B) and annular plaques on the forehead (C) secondary to phenobarbital.
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 25
Mucous Membranes Enanthem on buccal mucosa.
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 26
LABORATORY EXAMINATIONS Hemogram
Peripheral eosinophilia. Dermatopathology
Perivascular lymphocytes and eosinophils.
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 27
MANAGEMENT The definitive step in management is to
identify the offending drug and discontinue it. Symptomatic Treatment
Oral antihistamine to alleviate pruritus. Glucocorticoids
Potent Topical Preparation May help speed resolution of eruption.
Oral or IV Provides symptomatic relief. If offending drug cannot be substituted or omitted,
systemic glucocorticoids can be administered to treat the ACDR; also, to induce more rapid remission.
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 28
FIXED DRUG ERUPTION
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 29
FIXED DRUG ERUPTION
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 305 Nov 2015
FB: Eko Kepik - HP: 08122914685 31
PATHOGENESIS Unknown.
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 32
CLINICAL MANIFESTATION Drug History Patients frequently give a
history of identical lesion(s) occurring at the identical location.
Skin symptoms : Usually asymptomatic. May be pruritic, painful, or burning. Painful when eroded.
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 33
Time to onset of lesion(s) : Occur from 30 min to 8 h after ingestion of
drug in previously sensitized individual. Duration of lesion(s):
Lesions persist if drug is continued. Resolve days to few weeks after drug is
discontinued.
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 34
Skin Lesions The characteristic early lesion is a
sharply demarcated macule, round or oval in shape, occurring within hours after ingestion of the offending drug.
Initially erythema, then dusky red to violaceous.
Most commonly, lesions are solitary and can spread to become quite large (Fig. 22-9A), but they may be multiple (Fig. 22-9B) with random distribution;
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 35
Lesions become edematous, thus forming a plaque, which may evolve to become a bulla (Fig. 22-8B) and then an erosion.
Eroded lesions, especially on genitals or oral mucosa, are quite painful.
After healing, dark brown with violet hue postinflammatory hyperpigmentation.
Genital skin (Fig. 35-19) is frequently involved site, but any site may be involved; perioral, periorbital (Fig. 22-8A).
Occur in conjunctivae, oropharynx.
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 365 Nov 2015
FB: Eko Kepik - HP: 08122914685 37
LABORATORY EXAMINATIONS Dermatopathology
Similar to findings in erythema multiforme and/or TEN.
Patch Test Suspected drug can be placed as a patch
test at a previously involved site
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 38
MANAGEMENT Identify and withhold the offending drug. Non-eroded lesions can be treated with a
potent topical glucocorticoid ointment. Eroded cutaneous lesions can be treated
with an antimicrobial ointment and a dressing until the site is reepithelialized.
For widespread, generalized, and highly painful mucosal lesions, oral prednisone 1 mg/kg body weight tapered over a course of 2 weeks.
5 Nov 2015
FB: Eko Kepik - HP: 08122914685 39
THANK YOU
5 Nov 2015